Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis

Carucci, Sara;Balia, Carla;Gagliano, Antonella;Lampis, Angelico;Buitelaar, Jan K;Danckaerts, Marina;Dittmann, Ralf W;Garas, Peter;Hollis, Chris;Inglis, Sarah;Konrad, Kerstin;Kovshoff, Hanna;Liddle, Elizabeth B;McCarthy, Suzanne;Nagy, Peter;Panei, Pietro;Romaniello, Roberta;Usala, Tatiana;Wong, Ian C K;Banaschewski, Tobias;Sonuga-Barke, Edmund;Coghill, David;Zuddas, Alessandro

Last

2021-01-01

---

Abstract

Background: Methylphenidate (MPH) is an efficacious treatment for ADHD but concerns have been raised about potential adverse effects of extended treatment on growth. Objectives: To systematically review the literature, up to December 2018, conducting a meta-analysis of association of long-term (> six months) MPH exposure with height, weight and timing of puberty. Results: Eighteen studies (ADHD n = 4868) were included in the meta-analysis. MPH was associated with consistent statistically significant pre-post difference for both height (SMD = 0.27, 95% CI 0.16-0.38, p < 0.0001) and weight (SMD = 0.33, 95% CI 0.22-0.44, p < 0.0001) Z scores, with prominent impact on weight during the first 12 months and on height within the first 24-30 months. No significant effects of dose, formulation, age and drug-naïve condition as clinical moderators were found. Data on timing of puberty are currently limited. Conclusions: Long-term treatment with MPH can result in reduction in height and weight. However, effect sizes are small with possible minimal clinical impact. Long-term prospective studies may help to clarify the underlying biological drivers and specific mediators and moderators.